4.6 Article

Efficacy and safety analysis of TACE plus Donafenib plus Toripalimab versus TACE plus Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study

期刊

BMC CANCER
卷 23, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12885-023-11535-5

关键词

Hepatocellular carcinoma; Transarterial chemoembolization; Targeted therapy; Immunotherapy; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Interventional treatment

类别

向作者/读者索取更多资源

TACE combined with Donafenib and Toripalimab demonstrates superior efficacy and safety compared to TACE combined with Sorafenib in treating unresectable HCC patients. This combination therapy not only improves the objective response rate and disease control rate, but also prolongs progression-free survival and overall survival. Additionally, the occurrence of treatment-related adverse events is lower in the TACE + Donafenib + Toripalimab group compared to the TACE + Sorafenib group.
Objective To compare the efficacy and safety of TACE combined with Donafenib and Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), aiming to guide personalized treatment strategies for HCC and improve patient prognosis.Materials and methods A retrospective analysis was conducted on the clinical data of 169 patients with unresectable advanced-stage HCC who underwent treatment at the Interventional Department of Wuhan Union Hospital from January 2020 to December 2022. Based on the patients' treatment strategies, they were divided into two groups: TACE + Donafenib + Toripalimab group (N = 81) and TACE + Sorafenib group (N = 88). The primary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups' tumors. The secondary endpoint was the occurrence of treatment-related adverse events in the two groups of patients.Results The TACE + Donafenib + Toripalimab group showed higher ORR and DCR compared to the TACE + Sorafenib group (66.7% vs. 38.6%, 82.6% vs. 68.2%, P < 0.05). The TACE + Donafenib + Toripalimab group also demonstrated longer median progression-free survival (mPFS) (10.9 months vs. 7.0 months, P < 0.001) and median overall survival (mOS) (19.6 months vs. 10.9 months, P < 0.001) compared to the TACE + Sorafenib group. When comparing the two groups, the TACE + Sorafenib group had a higher incidence of grade 3-4 hypertension (14.8% vs. 4.9%, P = 0.041), higher incidence of diarrhea (all grades) (18.2% vs. 7.4%, P = 0.042), and higher incidence of hand-foot syndrome (all grades) (26.1% vs. 12.3%, P = 0.032).Conclusion TACE combined with Donafenib and Toripalimab demonstrates superior efficacy and safety in treating unresectable HCC patients. This combination therapy may serve as a feasible option to improve the prognosis of unresectable HCC patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据